Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Ardy Arianpour, William Moffitt, Mark McDonough, Judd Jessup, and More

Premium

Ardy Arianpour is now senior vice president of business development at Ambry Genetics. He previously served as vice president of business development at the company. Arianpour joined Ambry in 2009 after holding several positions at Cogenics.


Nanosphere's former president and CEO William Moffitt has taken on the post of executive chairman at GlySure, a UK-based company that has developed a glucose monitoring system.

Moffitt left Nanosphere in February. Before he ended his tenure at the Northbrook, Ill.-based molecular diagnostics firm, he was president and CEO of i-STAT, and prior to that, he held executive posts at Baxter Healthcare and American Hospital Supply.


Combimatrix's shareholders have re-elected their board of directors to continue serving until the 2014 shareholder meeting. The re-elected board includes President and CEO Mark McDonough, former CEO and executive chairman Judd Jessup, Chief Medical Officer Richard Hockett, Scott Gottlieb, Wei Richard Ding, and Jeremy Jones.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.